Crizotinib in the treatment of generalized non‑small‑cell lung cancer – a case report
MUDr. Leona Koubková
Pneumologická klinika 2. LF UK a FN v Motole, Praha
Targeted therapy on the basis of predictive biomarkers that predict the efficacy, at least some patients allows to individualize the treatment and in recent years led to improved treatment outcomes in patients with unfavorable diagnosis of NSCLC (non-small-cell lung cancer). One of these predictive biomarkers is a gene rearrangement EML-4-ALK and ROS1, where is indicated treatment with ALK and ROS1 inhibitors.
non-small-cell lung cancer, predictive biomarkers, gene rearrangement ALK, crizotinib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...